Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”The first generation of hemophilia A gene therapies changed the field in an important way.
The question is no longer simply whether gene therapy can reduce bleeding.
The question is whether gene therapy can deliver durable expression over time.
Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.
At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.
Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.
Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”
Stay updated with Hemostasis Today.
-
Jun 30, 2026, 05:55Benjamin YQ Tan: Exploring the Heart-Brain-Thrombosis Continuum
-
Jun 30, 2026, 05:37Maxime Dely: Blood Donation – Bridging the Global Gap in Access
-
Jun 30, 2026, 05:20Jenny Amphlett: A Decade of Excellence in Anticoagulation Care
-
Jun 30, 2026, 05:16Diana Langworthy: New Episode – Solving the DOAC vs. Warfarin Mystery in Cirrhosis
-
Jun 30, 2026, 05:06Brian Haddigan: Beyond Stent Design – The Importance of Blood Compatibility
-
Jun 30, 2026, 04:47Kaihang Wang: Portal Vein Thrombosis After Pediatric Liver Transplantation
-
Jun 30, 2026, 04:12Maia Meier: Driving Change for Women and Girls with Bleeding Disorders
-
Jun 30, 2026, 03:19Wolfgang Miesbach: Weight-Bearing Lunge Test for Ankle Assessment in Haemophilia?
-
Jun 30, 2026, 03:06Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?